GSK buys 35Pharma for $950m, targeting next-generation pulmonary hypertension therapy and the TGF-β superfamily

EUROPEAN BIOTECHNOLOGY MAGAZINE - GSK will pay $950m for Montreal-based 35Pharma to secure HS235, an investigational activin signalling inhibitor that has completed Phase I trials in healthy volunteers and is set to begin studies in pulmonary arterial hypertension (PAH) and pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF). Read more

Luke Miels, Chief Executive Officer, GSK Photo credit: GSK